Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Summary

This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Timeline

Start

2014-11-25

Primary completion

2018-11

Completion

2018-11

Drugs

Indications